Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

October 12, 2017: By Joan McKenna
Notal Vision's ForeseeHome monitoring device

Notal Vision’s ForeseeHome monitoring device

Notal Vision announced Oct. 5 that patients have used its ForeseeHome monitoring device 3 million times.

It is the first US FDA-cleared home monitoring system for patients with intermediate dry age-related macular degeneration (AMD) at risk for developing wet AMD.

The self-administered test is designed to detect wet AMD at an earlier stage, allowing doctors to treat patients sooner in disease progression and possibly prevent loss of sight.

The system received US clearance in December 2009 and was used in clinical research before being commercially launched in October 2013. It gained Medicare reimbursement in 2016.

In 2010, the National Eye Institute began using the ForeseeHome in a secondary study to AREDS2 in 1,500 patients. Ninety percent of patients who used the device twice weekly and progressed to wet AMD maintained 20/40 or better vision, compared with 62 percent of patients whose diagnosis was during a routine eye exam or visit triggered by symptoms.

Notal Vision is headquartered in Tel Aviv, Israel, with a US office and distribution center in Virginia.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Eylea Gains Approval in China for DME-Related Visual Impairment

Second Trial for Ophthalmic Industry Leader James Mazzo Ends in Hung Jury, Mistrial

Melgen Receives 17-Year Sentence for Medicare Fraud

NIH’s National Eye Institute Solicits Next-Generation Retina Organoids in $1 Million Prize Competition

Taiwan Liposome Company Registers for $50 Million IPO in US

US FDA Approves Icon Bioscience’s DEXYCU for Post-Cataract Surgery Inflammation

FDA’s Gottlieb Appears to Soften Stance on Compounding for Office Use

Genentech’s RG7716 Outperformed Ranibizumab in Phase II Study in Diabetic Macular Edema

Santen Reports Promising Data in Phase I/II Study in Refractory Wet AMD

Q Biomed Signs Agreement with Washington University for Novel Biomarker for Monitoring Glaucoma

pSivida’s Durasert for Posterior Segment Uveitis Yields Positive 12-Month Results in Second Phase III Study

Foundation Fighting Blindness Provides $7.5 Million to Help Develop ProQR’s Candidate for Usher Syndrome

Presbia Names Casey Lind as Chief Operating Officer, Magda Michna, MD, PhD, as Chief Clinical Officer

Astellas Acquires Universal Cells

Pixium Vision Completes Two Successful PRIMA Implantations in Atrophic Dry AMD Patients

Omeros Loses Pass-through Status for Omidria

USC Donations Drop $100 Million after Puliafito Scandal, Report Says

Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

Allergan’s Net Sales Climb 12 Percent in Q4-2017; Restasis Sales Grow Nearly 1 Percent

Lucentis’ US Sales Drop 11 percent in Q4-2017, Grow 1 Percent for Full 2017

Coming soon

2018 Retinal Surgical Devices Report: A Global Market Analysis for 2017 to 2023